Indications for BRIVIACT INJECTION:
Partial-onset seizures, as monotherapy or adjunctive treatment when oral administration is temporarily not feasible in patients ≥16yrs.
Interchangeable with other forms. Give by IV over 2–15mins; limit to 4 consecutive days of treatment. ≥16yrs: initially 50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily based on response and tolerability. Hepatic impairment: initially 25mg twice daily; max 75mg twice daily. Concomitant rifampin: double brivaracetam dosage.
<16yrs: not established.
BRIVIACT INJECTION Warnings/Precautions:
Increased risk of suicidal behavior or ideation; monitor for clinical worsening and/or any unusual changes. Monitor for neurological and psychiatric adverse reactions. Discontinue if hypersensitivity reactions occur. Hepatic impairment: adjust dose (see Adult). End-stage renal disease undergoing dialysis: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.
BRIVIACT INJECTION Classification:
BRIVIACT INJECTION Interactions:
Antagonized by rifampin (see Adult). Concomitant carbamazepine: may consider dose reduction if intolerant. May potentiate phenytoin; monitor phenytoin levels when adding or discontinuing brivaracetam from ongoing therapy. Concomitant levetiracetam: no added benefit.
Somnolence/sedation, dizziness, fatigue, nausea/vomiting; hematologic abnormalities.
To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.
Generic Drug Availability:
Tabs—60; Oral soln—300mL; Single-dose vials—10